Indications

• Hereditary Angioedema (see Angioedema, [[Angioedema]])

---

Pharmacology

• Plasma Kallikrein Inhibitor: decreases kallikrein-mediated synthesis of bradykinin

Metabolism

• xxxx

---

Administration

• SQ

Dose Adjustment

• Hepatic:
• Renal:

Adverse Effects

Allergic/Immunologic Adverse Effects

Anaphylaxis (see Anaphylaxis, [[Anaphylaxis]])

• Epidemiology: occurs in 3% of cases
• Clinical: usually occurs within 1 hr of administration

Other Adverse Effects

• xxx
• xxx
• xxx

---

References

• xxxx